Targeting oxidative stress and inflammasome-mediated inflammation may improve both molecular and clinical outcomes, highlighting the translational potential of the SIRT1/Nrf2/NLRP3 axis for personalized management of PD. The gene discussed is NLRP3; the disease is Parkinson disease.